Skip to main content
 
  • Engineering any genome, at any site, in any way

  • At the forefront of a revolutionary field offering profound benefits to human health and society

  • Focused on the advancement of new applications for CRISPR-based technologies

  • Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech

News

Caribou Biosciences' Co-Founder Dr. Jennifer Doudna and Chairman of the Board Rodolphe Barrangou Selected for 2016 Canada Gairdner Awards

March 24, 2016
BERKELEY, CA – March 24, 2016 – Caribou Biosciences, Inc., a developer of CRISPR technologies for precision cell engineering, announced today that co-founder Jennifer Doudna, Ph.D., and Rodolphe Barrangou, Ph.D., M.B.A., Chairman of...

Caribou Biosciences and Integrated DNA Technologies (IDT) Announce Non-Exclusive License Agreement for CRISPR-Cas9 Reagents

February 23, 2016
BERKELEY, CA, and CORALVILLE, IA – February 23, 2016 – Caribou Biosciences, Inc., a developer of CRISPR technologies for precision cell engineering, and Integrated DNA Technologies, Inc. (IDT), a producer of custom synthetic...

Our Approach

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing.  Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. 

Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

Learn More...